Essay on Drug Analysis : The Drug Ranolazine By Cv Therapeutics

1979 Words Nov 29th, 2016 8 Pages
In the case study distributed on November 1, drug dilemmas are examined when it comes to big, dominating pharmaceutical companies. For this particular case study, the drug ranolazine by CV Therapeutics was the main focus. One of the main topics is how big pharmaceutical companies charge so much for their final products while it doesn’t cost near as much to fabricate the drugs when most of the testing is done overseas. Marcia Angell, the former editor in chief of the New England Journal of Medicine, mentions how today’s drugs are not necessarily “new drugs” but improvements on old drugs that are already on the market. Companies still get away with charging more for this “new drug” when there is not chemical difference when compared to the older version. CV Therapeutics produced the drug ranolazine specifically for the treatment of angina, becoming the first new treatment in over twenty-five years. The drug was praised by many including the Journal of the American Medical Association for its ability to help patients whom standard therapies had failed. However, even though the drug is having a lot of success with patients in America, patients in Russia and Eastern Europe made up roughly 60 percent of the 1,000 or so test subjects that were involved in the studies that allowed CV Therapeutics to fabricate ranolazine. Now, CV Therapeutics is not offering ranolazine to the same patients whom aided in the pharmaceutical company’s development of the drug in the first place, which…

Related Documents